Q3 2023 EPS Estimates for Krystal Biotech, Inc. (NASDAQ:KRYS) Raised by Analyst

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) – Equities researchers at HC Wainwright lifted their Q3 2023 EPS estimates for Krystal Biotech in a note issued to investors on Monday, May 22nd. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($1.02) for the quarter, up from their previous estimate of ($1.30). The consensus estimate for Krystal Biotech’s current full-year earnings is ($5.85) per share. HC Wainwright also issued estimates for Krystal Biotech’s Q4 2023 earnings at ($0.93) EPS, FY2023 earnings at ($4.90) EPS, FY2024 earnings at ($3.10) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at $0.89 EPS and FY2027 earnings at $2.40 EPS.

Several other research firms also recently commented on KRYS. Stifel Nicolaus increased their target price on Krystal Biotech from $102.00 to $145.00 in a research report on Wednesday. Guggenheim raised their price objective on Krystal Biotech from $101.00 to $130.00 in a research report on Monday. Bank of America raised their price objective on Krystal Biotech from $105.00 to $118.00 in a research report on Sunday. William Blair restated an “outperform” rating on shares of Krystal Biotech in a research report on Wednesday, March 22nd. Finally, Chardan Capital raised their price objective on Krystal Biotech from $133.00 to $148.00 in a research report on Monday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $134.00.

Krystal Biotech Stock Performance

Shares of KRYS opened at $118.53 on Wednesday. Krystal Biotech has a 52-week low of $49.17 and a 52-week high of $123.84. The firm has a market capitalization of $3.06 billion, a PE ratio of -22.45 and a beta of 0.85. The stock has a 50 day simple moving average of $85.89 and a 200 day simple moving average of $80.77.

Krystal Biotech (NASDAQ:KRYS – Get Rating) last released its quarterly earnings results on Monday, February 27th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.01.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. State Street Corp raised its holdings in shares of Krystal Biotech by 52.3% during the first quarter. State Street Corp now owns 1,068,656 shares of the company’s stock valued at $71,108,000 after acquiring an additional 366,855 shares during the period. Braidwell LP bought a new position in Krystal Biotech during the fourth quarter valued at about $28,365,000. Avoro Capital Advisors LLC raised its holdings in Krystal Biotech by 24.1% during the first quarter. Avoro Capital Advisors LLC now owns 1,750,000 shares of the company’s stock valued at $140,105,000 after buying an additional 340,000 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of Krystal Biotech by 1,010.1% in the third quarter. Victory Capital Management Inc. now owns 303,599 shares of the company’s stock worth $21,161,000 after purchasing an additional 276,251 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in shares of Krystal Biotech by 74.2% in the first quarter. Dimensional Fund Advisors LP now owns 262,463 shares of the company’s stock worth $17,465,000 after purchasing an additional 111,822 shares during the period. 80.80% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Daniel Janney sold 7,900 shares of the company’s stock in a transaction on Wednesday, April 19th. The stock was sold at an average price of $90.32, for a total value of $713,528.00. Following the transaction, the director now directly owns 224,462 shares of the company’s stock, valued at approximately $20,273,407.84. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Dino A. Rossi sold 40,000 shares of the business’s stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $83.25, for a total value of $3,330,000.00. Following the completion of the sale, the director now directly owns 83,691 shares of the company’s stock, valued at $6,967,275.75. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Daniel Janney sold 7,900 shares of the business’s stock in a transaction dated Wednesday, April 19th. The stock was sold at an average price of $90.32, for a total transaction of $713,528.00. Following the transaction, the director now owns 224,462 shares in the company, valued at $20,273,407.84. The disclosure for this sale can be found here. Insiders sold 193,428 shares of company stock valued at $17,965,513 over the last 90 days. Company insiders own 17.00% of the company’s stock.

Krystal Biotech Company Profile

(Get Rating)

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization.